These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 7522948)

  • 1. Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epidoxorubicin, 5-fluorouracil regimen plus granulocyte colony stimulating factor for breast cancer therapy.
    Venturini M; Del Mastro L; Melioli G; Balleari E; Garrone O; Pasquetti W; Bason C; Ghio R; Bruzzi P; Rosso R
    Cancer; 1994 Oct; 74(8):2300-6. PubMed ID: 7522948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of whole blood and peripheral blood progenitor cells (PBPC) and new strategies for rescue after intensive cyclic chemotherapy in high-risk breast cancer.
    Filip S; Bláha M; Odrázka K; Mericka P; Vávrová J
    J Hematother Stem Cell Res; 2000 Feb; 9(1):31-8. PubMed ID: 10738969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection.
    Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K
    Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization.
    Passos-Coelho JL; Braine HG; Davis JM; Huelskamp AM; Schepers KG; Ohly K; Clarke B; Wright SK; Noga SJ; Davidson NE
    J Clin Oncol; 1995 Mar; 13(3):705-14. PubMed ID: 7533827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematological recovery and peripheral blood progenitor cell mobilization after induction chemotherapy and GM-CSF plus G-CSF in breast cancer.
    Charrier S; Chollet P; Bay JO; Curé H; Kwiatkowski F; Portefaix G; Communal Y; Bétail G; Plagne R; Chassagne J
    Bone Marrow Transplant; 2000 Apr; 25(7):705-10. PubMed ID: 10745254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support.
    Papadopoulos KP; Ayello J; Tugulea S; Heitjan DF; Williams C; Reiss RF; Vahdat LT; Suciu-Foca N; Antman KH; Hesdorffer CS
    J Hematother; 1997 Feb; 6(1):61-8. PubMed ID: 9112219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin.
    Brugger W; Bross K; Frisch J; Dern P; Weber B; Mertelsmann R; Kanz L
    Blood; 1992 Mar; 79(5):1193-200. PubMed ID: 1371415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells.
    Vogel W; Kunert C; Blumenstengel K; Fricke HJ; Kath R; Sayer HG; Höffken K
    J Cancer Res Clin Oncol; 1998; 124(6):341-5. PubMed ID: 9692843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.
    Brugger W; Birken R; Bertz H; Hecht T; Pressler K; Frisch J; Schulz G; Mertelsmann R; Kanz L
    Br J Haematol; 1993 Jul; 84(3):402-7. PubMed ID: 7692928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
    Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
    J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study Group.
    Narabayashi M; Takeyama K; Fukutomi T; Tokuda Y; Tajima T; Okumura A; Chou T; Sano M; Makino H; Igarashi T; Sasaki Y; Imoto S; Ogura M; Morishima Y; Murai H; Okamoto S; Ikeda T; Kasai M; Yokozawa T; Tobinai K
    Jpn J Clin Oncol; 1999 Jun; 29(6):285-90. PubMed ID: 10418556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF.
    Ballestrero A; Ferrando F; Garuti A; Basta P; Gonella R; Stura P; Mela GS; Sessarego M; Gobbi M; Patrone F
    J Clin Oncol; 1999 Apr; 17(4):1296. PubMed ID: 10561192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer.
    Burns LJ; Weisdorf DJ; DeFor TE; Repka TL; Ogle KM; Hummer C; Miller JS
    Exp Hematol; 2000 Jan; 28(1):96-103. PubMed ID: 10658681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor.
    Schwartzberg LS; Birch R; Hazelton B; Tauer KW; Lee P; Altemose R; George C; Blanco R; Wittlin F; Cohen J
    J Hematother; 1992; 1(4):317-27. PubMed ID: 1285381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reinfusion and serial measurements of carboplatin-mobilized peripheral-blood progenitor cells in patients receiving multiple cycles of high-dose chemotherapy.
    Shea TC; Mason JR; Breslin M; Bissent E; Mullen M; Taetle R
    J Clin Oncol; 1994 May; 12(5):1012-20. PubMed ID: 7513018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mobilization of peripheral blood progenitor cells after induction chemotherapy (THP-doxorubicin-vinorelbine-cyclophosphamide-fluorouracil) and granulocyte colony-stimulating factor in breast cancer.
    Charrier S; Chassagne J; Curé H; Bay JO; Communal Y; Portefaix G; Ferrière JP; Bétail G; Plagne R; Chollet P
    Bone Marrow Transplant; 1998 Nov; 22(9):845-51. PubMed ID: 9827811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
    Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
    J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal timing for collections of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in advanced breast cancer.
    Ho AD; Glück S; Germond C; Sinoff C; Dietz G; Maruyama M; Corringham RE
    Leukemia; 1993 Nov; 7(11):1738-46. PubMed ID: 7901454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients.
    Filip S; Vanásek J; Bláha M; Mericka P; Vávrová J; Podzimek K
    Neoplasma; 1999; 46(3):166-72. PubMed ID: 10613592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer.
    Venturini M; Del Mastro L; Testore F; Danova M; Garrone O; Lanfranco C; Latini F; Sertoli MR; Lionetto R; Queirolo P; Ardizzoni A; Rosso R
    Cancer Chemother Pharmacol; 1996; 38(6):487-94. PubMed ID: 8823488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.